17
Views
3
CrossRef citations to date
0
Altmetric
Editorial Comment

Attaining United States and European Guideline LDL-C Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study)

&
Pages 205-207 | Published online: 05 Aug 2008

References

  • Garmendia, F., Brown, A. S., Reiber, I. and Adams, P. C. (2000). Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr. Med. Res. Opin., 16(3), 208–219.
  • Wood, D., Durrington, P., Poulter, N., McInnes, G., Rees, A. and Wray, R. on behalf of the Societies (British Cardiac Society, British Hypertension Society, British Hyperlipidaemia Association and British Diabetic Association) (1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart, 80 (Suppl 2), S1–S29.
  • White, C. W. (1998). Benefit of aggressive lipid-lowering therapy: insights from the post-coronary artery bypass graft study and other trials. Am. J. Med., 105 (Suppl 1A), 63S–68S.
  • Phillips, C., Smith, R. and Pittard, J. (2000). Secondary prevention with statin therapy: a budgetary-impact assessment for UK primary care. J. Med. Econ., 3, 21–33.
  • Mikhailidis, D. P. and Wierzbicki, A. S. (2000). HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Cum Med. Res. Opin., 16, 139–146.
  • Boden, W. E. and Pearson, T. A. (2000). Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am. J. Cardiol., 85, 645–650.
  • Wierzbicki, A. S., Crook, M. A., Nair, D. R., Mikhailidis, D. P. and Winder, A. F. (2000). More on the effect of atorvastatin on plasma fibrinogen levels in primary hyper-cholesterolaemia. Atherosclerosis, 148, 204.
  • Furberg, C. D., Herrington, D. M. and Psaty, B. M. (1999). Are drugs within a class interchangeable? Lancet, 354, 1202–1204.
  • Haffner, S. M., Alexander, C. M., Cook, T. J., Boccuzzi, S. J., Musliner, T. A., Pedersen, T. R., Kjekshus, J. and Pyorala, K. (1999). Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intent Med., 159, 2661–2667.
  • Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, M. et al. (2000). Effect of pravastatin on coronary disease events in subgrouups by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation, 102, 1893–1900.
  • Wierzbicki, A. S., Lumb, P. J., Chik, G. and Crook, M. A. (2000). High-density lipo-protein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolaemia. Am. J. Cardiol., 86, 547–549.
  • Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet, 344, 1383–1389.
  • Pedersen, T. R., Wilhelmsen, L., Faergeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L. et al. (2000). Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am. J. Cardiol., 86, 257–262.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.